|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,006 DKK | +0.30% |
|
+1.79% | +44.05% |
| 12:42pm | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
| 09:22am | NOVO NORDISK : UBS gives a Neutral rating | ZD |
June 24 (Reuters) - Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.
The U.S. Food and Drug Administration on Friday tentatively approved London-based Hikma Pharmaceuticals' version of Victoza, according to the agency's website. (Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 1,891 GBX | +0.85% | -4.06% | 5.26B | ||
| 1,006 DKK | +0.30% | +1.79% | 638B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +44.05% | 638B | |
| +56.49% | 819B | |
| -6.38% | 351B | |
| +18.18% | 329B | |
| +9.59% | 298B | |
| +16.57% | 242B | |
| +2.04% | 225B | |
| +13.31% | 217B | |
| +8.76% | 168B | |
| -2.81% | 158B |
NOVO NORDISK A/S 
